JBSNF-000088 (6-Methoxynicotinamide), a analog of nicotinamide (NA), is a potent and orally active Nicotinamide N-methyltransferase (NNMT) inhibitor with IC 50 s of 1.8 μM, 2.8 μM, and 5.0?μM for human NNMT, monkey NNMT and mouse NNMT, respectively. JBSNF-000088 inhibits NNMT activity, reduces MNA levels and drives insulin sensitization, glucose modulation and body weight reduction in animal models of metabolic disease.
JBSNF-000088 (6-Methoxynicotinamide) has IC50 values are 1.6 and 6.3?μM for U2OS or differentiated 3T3L1 cells. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
JBSNF-000088 (6-Methoxynicotinamide) (50?mg/kg; oral route of administration for four weeks) shows statistically significant reduction in body weight (%) and leads to a statistically significant reduction in fed blood glucose on day 21.
JBSNF-000088 (50?mg/kg; oral gavage administration; twice daily for four weeks) leads to a statistically significant improvement in oral glucose tolerance on day 28 with glucose tolerance being normalized.
JBSNF-000088 (1 mg/kg; intravenous administration; for 4 hours) results in low plasma clearance of 21?mL/min?kg and the volume of distribution at steady state of 0.7?L/kg, a very short plasma half-life of 0.5?hours upon intravenous administration.
JBSNF-000088 (10 mg/kg; oral gavage; for 4 hours) results in a Cmax of 3568 ng/mL with a T max value of 0.5?hours, indicating rapid absorption in the intestine, and half-lif
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
参考文献
[1]. Kannt A, et al. A small molecule inhibitor of Nicotinamide N-methyltransferase for the treatment of metabolic disorders. Sci Rep. 2018 Feb 26;8(1):3660.
溶解度数据
In Vitro: DMSO : ≥ 100 mg/mL (657.25 mM)H2O : 1 mg/mL (6.57 mM; Need ultrasonic)